The Significance of Transcription Factors, miRNAs, and lncRNAs in Anticancer Drug Development
A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 99
Special Issue Editors
2. Fellow, National Academy of Inventors, Tampa, FL 33612, USA
3. Academician, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 11529, Taiwan
Interests: chromatin structure and function; tetra-O-methyl nordihydroguaiaretic acid (M4N, terameprocol); oncogenic development in humans; chemotherapeutic drug treatments; viral replication; gene functions
Special Issues, Collections and Topics in MDPI journals
Interests: anticancer drug; combination drug treatment; transcription factor; gene regulation; alternative splicing; cancer metabolism; mitochondria; apoptosis and hypoxia
Special Issue Information
Dear Colleagues,
Recent progress in systems biology has shown that several specific factors are participants of a network that function as master regulators of cancer. These factors are usually transcription factors, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) in control of the expression of various genes which play important roles in the regulation of cancer development. This suggests that there may be a way to induce unfavorable effects on cancer development and progression by modulating the activity and/or expression of these specific factors. In this Special Issue, we will focus on studies that investigate the roles and mechanisms of transcription factors, miRNAs, and lncRNAs in the regulation of the expression of cancer-related genes and/or proteins, and explore the search for potential drugs that cause adverse effects on cancer by modulating the activity of these specific factors and thus manipulating the activity and/or expression of various cancer-related genes and/or proteins. In other words, this Special Issue is about the effort to discover potentially effective anticancer drugs by targeting transcription factors, miRNAs, and lncRNAs which function as master regulators of cancer.
Prof. Dr. Ru Chih C. Huang
Dr. Kotohiko Kimura
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- transcription factors
- microRNAs (miRNAs)
- long non-coding RNAs (lncRNAs)
- anticancer drugs
- cancer
- coactivators
